With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

This drug is again a once-a-week injection that combines the long-acting amylin analogue, cagrilintide, with semaglutide. It works in a similar way to just semaglutide, but may offer better ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

In Novo Nordisk’s trial, there were only 1.2 GI adverse events per patient year in the cagrilintide treatment arm, versus 2.6 for semaglutide and 2.8 for CagriSema. Unlike incretin therapies ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...